Development and validation of an immune-related prognostic signature in lung adenocarcinoma

Sijin Sun | Wei Guo | Zhen Wang | Xin Wang | Guochao Zhang | Hao Zhang | Renda Li | Yibo Gao | Bin Qiu | Fengwei Tan | Yushun Gao | Qi Xue | Shugeng Gao | Jie He

Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Chaoyang District, Beijing, China

Correspondence
Dr. Jie He, Dr. Shugeng Gao and Dr. Yibo Gao, Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Chaoyang District, Beijing, China. Emails: prof.jiehe@gmail.com; gaoshugeng@vip.sina.com; gaoyibo@cicams.ac.cn

Funding information
National Key R&D Program of China, Grant/Award Number: 2017YFC1311000 and 2018YFC1312100; CAMS Initiative for Innovative Medicine, Grant/Award Number: 2017-12M-1-005, 2017-12M-2-003 and 2019-12M-2-002; Chinese Academy of Medical Sciences, Grant/Award Number: 2018PT32033 and 2017PT32017; Ministry of Education, Grant/Award Number: IRT_17R10; Peking Union Medical College Youth Fund, Grant/Award Number: 3332018144

Abstract
Background: Lung adenocarcinomas (LUAD) is the most common histological subtype of lung cancers. Tumor immune microenvironment (TIME) is involved in tumorigeneses, progressions, and metastases. This study is aimed to develop a robust immune-related signature of LUAD.

Methods: A total of 1774 LUAD cases sourced from public databases were included in this study. Immune scores were calculated through ESTIMATE algorithm and weighted gene co-expression network analysis (WGCNA) was applied to identify immune-related genes. Stability selections and Lasso COX regressions were implemented to construct prognostic signatures. Validations and comparisons with other immune-related signatures were conducted in independent Gene Expression Omnibus (GEO) cohorts. Abundant infiltrated immune cells and pathway enrichment analyses were carried out, respectively, through ImmuCellAI and gene set enrichment analysis (GSEA).

Results: In Cancer Genome Atlas (TCGA) LUAD cohorts, immune scores of higher levels were significantly associated with better prognoses ($P < .05$). Yellow ($n = 270$) and Blue ($n = 764$) colored genes were selected as immune-related genes, and after univariate Cox regression analysis ($P < .005$), a total of 133 genes were screened out for subsequent model constructions. A four-gene signature (ARNTL2, ECT2, PP1A, and TUBA4A) named IPSLUAD was developed through stability selection and Lasso COX regression. It was suggested by multivariate and subgroup analyses that IPSLUAD was an independent prognostic factor. It was suggested by Kaplan-Meier survival analysis that eight out of nine patients in high-risk groups had significantly worse prognoses in validation data sets ($P < .05$). IPSLUAD outperformed other signatures in two independent cohorts.

Conclusions: A robust immune-related prognostic signature with great performances in multiple LUAD cohorts was developed in this study.
According to estimates of cancer incidence in GLOBOCAN 2018, lung cancers remain a leading cause of cancer-related deaths, which are cancers with the highest death incidence worldwide. Approximately, 85% of lung cancers are NSCLCs, which can be further divided into three subtypes: large cell carcinomas, squamous cell carcinomas, and lung adenocarcinomas (LUAD). In most countries, LUAD is the most common histological subtype, which is a result of an increasing number of nonsmokers. With rapid evolutions of precision medicines, novel therapeutic strategies, especially immunotherapies, have been proposed to improve clinical outcomes of LUAD patients. However, only a fraction of patients was benefited from immunotherapies, leaving urgencies of finding potential biomarkers for efficient and prognostic predictions.

Cytotoxic T-lymphocyte-associated Antigen 4 (CTLA-4) and Programmed Death 1 (PD-1) immune checkpoints start a new paradigm shift in the field of immunotherapies. Mechanisms of immune checkpoint inhibitors (ICIs) targeting at these molecules are to relieve certain inhibitory pathways and thus, boosting the immune system to generate antitumor activities. Accordingly, efficacies of ICIs are considered strongly associated with hosts' immune systems and tumor immune microenvironments (TIME). Crosstalk between cancer cells and TIME was sophisticated comprising both protumorigenic and antitumorigenic manners. A T cell inflamed TIME induced by a CDK4/6 Inhibitor was shown to enhance efficacies of ICIs in vitro. Therefore, in-depth understanding of TIME can assist identifications of novel predictive biomarkers and developments of new therapeutic strategies.

With diminishing costs, high-throughput sequencing has emerged as a commonplace technology in the field of molecular biology. Computational algorithms, including Cibersort, Timer, and ImmuCellAI, have also been developed for assessments on abundance of infiltrated immune cells based on gene expression profiles. Altogether, these techniques provided valid and economical methods for providing detailed TIME profiles. Recently, several studies have been devoted to constructing immune-related signatures in LUAD and. Gene selections in their studies were based on prior knowledge sourced from external databases or differentially expressed genes (DEGs). Models based on these criteria might exclude immune-related genes that had not yet been confirmed or prognostic genes without different expressions. In addition, models containing too many genes limited feasibilities of their clinical applications. Therefore, there is an urgent need to construct a robust and simple immune-related prognostic signature.

In this study, immune scores of each case related to TCGA-LUAD were first calculated through ESTIMATE algorithm, then, weighted gene co-expression network analysis (WGCNA) was applied to identify immune-related modules. After that, a three-gene prognostic model was constructed based on stability selection and Lasso COX regression, whose effectiveness was further evaluated based on nine independent data sets and compared with other previously reported immune-related signatures. Finally, it was suggested by infiltrated immune cells and pathway enrichment analysis that our prognostic signature was closely related to components of innate immunities. In conclusion, we constructed a robust immune-related signature based on transcriptomics.

**2 MATERIALS AND METHODS**

**2.1 Data acquisition and preprocessing**

RNA-seq mRNA expression profiles and clinical information of TCGA-LUAD cohorts were downloaded from the Cancer Genome Atlas (TCGA) Genomic Data Commons Data Portal (https://portal.gdc.cancer.gov/). Microarray-based data about expressions, which contained nine Gene Expression Omnibus (GEO) data sets, was obtained from official website of GEO (https://www.ncbi.nlm.nih.gov/geo/) via GEOquery R package. Only patients with pathologically confirmed LUAD and complete information about transcriptomics overall survivals (OS) could be considered. Finally, a total of 1774 LUAD cases (TCGA:504, GEO:1270) sourced from TCGA and GEO databases were included in our study.

For TCGA-LUAD cohorts, paired-normal samples were first removed according to their TCGA barcodes. Then, Fragments per Kilobase Million (FPKM) values were transformed into Transcripts Per Million (TPM). Average value of genes with multiple probes was used as their expression value.
2.2 Evaluating tumor microenvironment in TCGA-LUAD cohort

ESTIMATE is a computerized algorithm which can be used to infer infiltration levels of stromal and immune cells in tumor tissues based on expression profiles.\(^{18}\) Stromal, immune, and ESTIMATE scores of each sample in TCGA-LUAD cohorts were downloaded from the official website (https://bioinformatics.mdanderson.org/estimate/). Survival and association analyses were performed between tumor stages and these scores.

2.3 Construction of weighted gene co-expression networks and identification of immune-related modules

WGCNA is a systematic biological method developed by Langfelder et al.\(^{19}\) It can be used to cluster highly correlated genes into modules and relative modules to phenotypes of interest. The WGCNA package of R software (http://www.r-project.org/) was used for network developments and visualizations. In network construction processes, soft thresholding power \(\beta\) was chosen as the lowest power with which fit index of scale-free topology reached 0.90. The minimum module size was set as 30. After clustering, modules were displayed together through a dendrogram with colored assignments. To identify immune-related modules, a module-trait relationship heatmap was drawn with correlated coefficients and \(P\)-value. Two modules, which were positively and negatively related to immune scores, respectively, were selected after comprehensive considerations on both module size (\(n > 100\)) and significances of the association.

2.4 Development and validation of the immune-related prognostic signature for lung adenocarcinomas (IPSLUAD)

A prognostic signature was developed in the following steps. First, expression values of 1057 genes were extracted from two selected modules of TCGA-LUAD cohort. Univariate Cox proportional hazard regressions were performed on these genes to identify factors related to prognoses (\(P < .05\)). Then, stability selection method was implemented to further narrow the scope through R package c060.\(^{20}\) The logic of stability selection is to induce additional randomizations and find out which features are consistently important in every subsampling step. Finally, a Lasso-penalized Cox model was applied to construct a prognostic model based on genes selected in previous steps through R package glmnet. A 10-fold cross validation was performed to determine the optimal value of Lasso penalty parameter. Coefficients of each gene in the model were determined by Lasso-penalized Cox model. The formula is:

\[
\sum_{k=0}^{n} \beta_k G_k,
\]

where \(\beta_k\) is coefficient of Gene \(k\), and \(G_k\) is the normalized expression value of Gene \(k\). Survival analyses were performed in TCGA-LUAD cohort using Kaplan-Meier estimator and multivariate Cox regression. Cutoff value was set as median of IPSLUAD score.

To further validate prognostic value of IPSLUAD, Kaplan-Meier survival analysis and Cox regression were performed in nine independent GEO LUAD data sets (GSE3141, GSE13213, GSE14814, GSE29016, GSE30219, GSE31210, GSE37745, GSE50081, and GSE68465)\(^{21-28}\) and,\(^{29}\) where cutoff value was set as median of IPSLUAD score. Gene expression values were normalized and scaled before validations. Area under the curve (AUC) of each data set was calculated for detailed evaluations.

2.5 Estimating immune cell infiltrations between high-risk and low-risk groups stratified by IPSLUAD

Infiltrated immune cells, particularly T cells, play indispensable roles in tumor immunotherapies. To compare infiltrated immune cells in samples with different IPSLUAD scores, ImmuCellAI was adopted to calculate the abundance of 24 immune cell types including 18 T-cell subsets. For cells with a median abundance that was higher than 0.1 and significant differences among groups (\(P < .05\)), association analyses between markers of these cells and IPSLUAD scores were performed to validate those differences. Cell markers were chosen according to CellMarker database.\(^{30}\)

2.6 Functional enrichment analysis of IPSLUAD using gene set enrichment analysis (GSEA)

To further understand biologic functions of IPSLUAD, GSEA was performed on TCGA-LUAD cohort based on GO Biological Process Ontology and KEGG gene sets.\(^{31}\) False discovery rate (FDR) was introduced as a control of Type I errors, and FDRs lower than 0.05 were considered significant. All the analyses were implemented through GSEA software (version 4.0.2).

2.7 Comparison between IPSLUAD and other existing immune-related signatures

In order to further evaluate prediction accuracies of IPSLUAD, we compared IPSLUAD with other immune-related
signatures ranging from three to thirty genes (Table S3). Two large independent cohorts (n > 200, GSE31210, GSE68465) were employed for comparisons. Risk scores of each signature were calculated based on normalized expression values and coefficients provided by original articles. Two-year and five-year AUCs were calculated and compared based on two data sets.

2.8 | Statistical analysis

Continuous variables were summarized through mean and standard deviations and compared through Wilcoxon test. Categorized variables were presented by frequency (n) and proportion (%), and then compared through ANOVA. Both Cox proportional hazard model and Log-rank test were applied to survival analyses, all of which were performed through R software (Version 3.6.3, The R Foundation for Statistical Computing). P values were two-side and were considered to be statistically significant if they were lower than .05.

3 | RESULTS

3.1 | Association between ESTIMATE-calculated scores and clinicopathological indicators

The whole processes of signature constructions and data analyses were shown in Figure 1. After excluding 13 cases with incomplete stages or survival information, 504 cases in TCGA-LUAD cohort were eligible for analyses. In each sample, stromal, immune and ESTIMATE scores were obtained, which, respectively, ranged from −1779.3 to 2106.9, −932.6 to 3237.6, and −2338.0 to 4907.6. In difference comparisons, immune and ESTIMATE scores were significantly associated with pathologic stages (Figure 2A-C, P < .05). The lowest stromal, immune, and ESTIMATE scores were all found in cases of Stage IV, which was the most progressive. In addition, cases with higher stromal, immune or ESTIMATE scores tended to have a better prognosis than those with scores of lower levels (Figure 2D-F).

![Figure 1: Flowchart of developments and validations of IPSLUAD](image-url)
3.2 Construction of co-expression modules and identification of modules associated with immune scores

Network constructions and module detections were followed by a step-by-step approach. First, soft threshold power 5 was chosen to calculate adjacencies since it was the lowest power with which fit index of scale-free topologies reached 0.90 (Figure 3A and B). Then, module identifications were performed through a dynamic tree cut with a deepSplit parameter set as 2. After merging similar modules, a total of 23 modules were identified and clustering dendrograms were presented (Figure 3C). A heatmap was drawn to shown correlated modules, in which red color represented positive

**FIGURE 2** Associations between immune/stromal/ESTIMATE scores and clinicopathological indicators. A-C, Differences among stromal/immune/ESTIMATE scores in different pathologic stages. Asterisk (*) indicated a significant difference between two groups ($P < .05$). D-F, Survival analyses of stromal/immune/ESTIMATE scores through Kaplan-Meier curve with log-rank test.
correlations and blue color represented negative ones (Figure S2A). To identify immune-related modules, module-trait association plots were presented (Figure S1). Results demonstrated that the top three modules with the greatest positive associations were colored with Yellow, Blue, and Tan, while the top three ones with the greatest negative associations were colored with Black, Purple, and Blue. Among these modules, genes colored with Blue (n = 764) and Yellow (n = 270) were selected in module constructions based on module sizes (n > 200) and association significances. Finally, association analyses of Gene Significances (GS) and module membership (MM) were performed on Blue and Yellow modules. GSs of all the above three scores were significantly (P < .05) associated with MM in these two modules (Figure S2B-G).

3.3 Construction of IPSLUAD in TCGA-LUAD cohort

A total of 1034 genes were selected through previous steps (Table S1). To explore genes significantly associated with OS of patients with LUAD, univariate Cox regression analysis was performed and genes with P values of lower than .005 were chosen. 133 genes were screened out and selected for constructions of subsequent models (Table S2). Stability selection was first implemented to identify important features, and estimated sets of stable features comprised four genes, namely Aryl Hydrocarbon Receptor Nuclear Translocator Like 2 (ARNTL2), Epithelial Cell Transforming 2 (ECT2), Peptidylprolyl Isomerase A (PPIA), and Tubulin Alpha 4a (TUBA4A) (Figure S3A). Then, the optimal value of Lasso penalty parameter λ was determined as 0.0048 through 10-fold cross validation (Figure S3B-C). λ was then substituted into the model to generate coefficients of each gene. The final IPSLUAD was calculated as follows: (0.2319 × EXPARNTL2) + (0.1595 × EXPECT2) + (0.1611 × EXPPPIA) + (0.1286 × EXPTUBA4A).

IPSLUAD of each patient in TCGA-LUAD was calculated, and high-/low-risk groups were divided with median IPSLUAD as cutoff. Distributions of risk scores, survival statuses, and four-gene expression profiles were shown in Figure 4A. It was demonstrated by association analyses that factors including genders, T Stage, N Stage, pathological stages, and survival statuses were significantly correlated (P < .05) with different IPSLUAD groups (Table 1). Patients in high-risk group had significantly worse prognoses than those in low-risk group (Log-rank P < .05) (Figure 4B). In subgroup analyses, a significantly shorter OS was shown in high-risk group than low-risk group in Stage I and III (Log-rank P < .05) (Figure 4C and E). A similar trend was found.
among patients in Stage II, although there were no statistical significances (Log-rank $P = .050$) (Figure 4D). Univariate Cox regressions showed that T Stage, lymph node involvements, distant metastases, pathological stage, and IPSLUAD were significantly associated with OS (Table 2). Further, multivariate Cox regressions demonstrated that T Stage, lymph node involvements, and IPSLUAD were independent prognostic factors (Table 2).

### 3.4 Validation of IPSLUAD in nine GEO data sets

Summaries of the nine GEO data sets were shown in Table 3. In each data set, patients were stratified into high-/low-risk groups according to the median of IPSLUAD. It was suggested by Kaplan-Meier survival analyses that patients in high-risk group had significantly worse prognoses in eight out of nine data sets (88.9%) (Figure 5A-D, I-K, Q). The same trend was also observed in IPSLUAD of one remaining data set, though it was not statistically significant (Figure 5L). AUC was also calculated to evaluate abilities of IPSLUAD, which was ranged from 0.617 to 0.753 in the nine data sets (Figure 5E-H, M-P, R). Importantly, there were five data sets (GSE3141, GSE13213, GSE29016, GSE31210, and GSE68465) with AUC values that were higher than 0.7.

### 3.5 Comparisons between IPSLUAD and other existing immune-related prognostic signatures

Characteristics of other immune-related signatures used in this study were summarized in Table 4. Two largest GEO cohorts (GSE31210, GSE68465) with sample sizes higher than 200 were used in model comparisons. GSE31210 was an early-stage cohort: all patients were in Stage I or II, while GSE68465 was a multi-site cohort comprising both early-stage patients and those in more advanced stages. For all comparisons in these two cohorts, IPSLUAD outperformed other signatures with superior predictive performances according to AUC values (0.75 vs 0.64-0.73; 0.70 vs 0.49-0.66; 0.72 vs 0.40-0.51; 0.66 vs 0.43-0.52) (Figure 6A-D).

**FIGURE 4** Prediction performances of IPSLUAD in TCGA-LUAD cohort. A, Distributions of risk scores (top), survival statuses of patients in low-risk and high-risk groups (middle), and four-gene expression profiles of each patient (bottom). B-E, Kaplan-Meier curves of OS between low-risk and high-risk groups based on whole-TCGA cohort (B), Stage I (C), Stage II (D), and Stage III subgroup (E)
3.6  Estimating the composition of infiltrated immune cells

To further characterize immune microenvironment of tumors, ImmuCellAI was employed to estimate the abundance of 24 types of immune cells in TCGA-LUAD cohort based on RNA-Seq data. Abundant immune cell populations with various kinds in each sample were shown in Figure 7A. Several cell types, namely CD4 naïve T cells, exhausted T cells (Tex), Type 1 regulatory T cells (Tr1), natural regulatory T (nTreg), Th1, Th2, Th17, Tfh, effector memory T (Tem) cells, natural killer T (NKT) cells, mucosal-associated invariant T cells (MAIT), dendritic cells (DC), B cells, monocytes, macrophages, natural killer cells (NK), Neutrophil, Gamma delta T cells (Tgd), CD4 T cells, and CD8 T cells, were significantly different \( (P < .05) \) in high-risk and low-risk groups (Figure 7B).

### TABLE 1  Correlations between IPSLUAD and clinicopathological parameters of 465 patients in TCGA-LUAD cohort

| Category          | Cases, 465 (100%) | IPSLUAD Low (n = 232) | IPSLUAD High (n = 233) | \( P \) value |
|-------------------|-------------------|-----------------------|------------------------|--------------|
| Age, mean (SD)    |                   | 66.1 (9.5)            | 64.3 (10.5)            | 0.060        |
| Gender            |                   |                       |                        |              |
| Male              | 211 (45.4%)       | 90 (38.8%)            | 121 (51.9%)            | 0.005        |
| Female            | 254 (54.6%)       | 142 (61.2%)           | 112 (48.1%)            |              |
| Smoking           |                   |                       |                        |              |
| Ever              | 400 (86.0%)       | 199 (85.8%)           | 201 (86.3%)            | 0.985        |
| Never             | 65 (14.0%)        | 33 (14.2%)            | 32 (13.7%)             |              |
| T stage           |                   |                       |                        |              |
| T1                | 161 (34.6%)       | 98 (42.2%)            | 63 (27.0%)             | 0.006        |
| T2                | 245 (52.7%)       | 110 (47.4%)           | 135 (57.9%)            |              |
| T3                | 44 (9.4%)         | 17 (7.3%)             | 27 (11.6%)             |              |
| T4                | 15 (3.2%)         | 7 (3.0%)              | 8 (3.4%)               |              |
| N stage           |                   |                       |                        |              |
| N0                | 314 (67.5%)       | 175 (75.4%)           | 139 (59.7%)            | 0.004        |
| N1                | 84 (18.1%)        | 33 (14.2%)            | 51 (21.9%)             |              |
| N2                | 65 (14.0%)        | 23 (9.9%)             | 42 (18.0%)             |              |
| N3                | 2 (0.4%)          | 1 (0.4%)              | 1 (0.4%)               |              |
| M stage           |                   |                       |                        |              |
| M0                | 444 (95.5%)       | 225 (97.0%)           | 219 (94.0%)            | 0.184        |
| M1                | 21 (4.5%)         | 7 (3.0%)              | 14 (6.0%)              |              |
| TNM stage         |                   |                       |                        |              |
| I                 | 257 (55.3%)       | 146 (62.9%)           | 111 (47.6%)            | 0.005        |
| II                | 112 (24.1%)       | 51 (22.0%)            | 61 (26.2%)             |              |
| III               | 75 (16.1%)        | 28 (12.1%)            | 47 (20.2%)             |              |
| IV                | 21 (4.5%)         | 7 (3.0%)              | 14 (6.0%)              |              |
| Status            |                   |                       |                        |              |
| Survival          | 300 (64.5%)       | 172                   | 128                    | <0.001       |
| Death             | 165 (35.5%)       | 60                    | 105                    |              |

Significant values of \( P < 0.05 \) is indicated in bold.

3.7  Associations between IPSLUAD and immune cell markers

Different abundances of infiltrated immune cells between high-risk and low-risk groups were further validated through correlation analyses on gene markers and IPSLUAD. Markers significantly correlated with IPSLUAD included CD4 for CD4 T cells, CD66b and CD11b for neutrophil, CD56, CD16, and CD94 for NK cells, CD206 for M2 macrophages, CD14 for monocytes, CD19 and CD79A for B cells, CD11c and HLA-DRA for dendritic cells, BCL6 and CD185 for Tfh, CD196, RORC, STAT3 for Th17, STAT1 for Th1 and STAT5B and HELIOS for Tregs (Table 5). It was suggested by these findings that IPSLUAD was strongly linked with innate immunities since it was closely related to several critical innate immunity-related components (neutrophil, NK cells, and dendritic cells).
To further investigate molecular functions of IPSLUAD in immune systems, a GSEA was performed based on GO Biological Process Ontology and KEGG gene sets. Two significant immune-related pathways were identified, namely innate immune response activating cell surface receptor signaling and interleukin 1 mediated signaling pathway (Figure 8A-D). Again, close associations between genes of IPSLUAD and innate immunities were validated through this result.

### TABLE 2  Univariate analysis and multivariate analysis of risk factors for prognosis in TCGA-LUAD cohort

| Risk factor                  | Univariate analysis | Multivariate analysis |
|------------------------------|---------------------|-----------------------|
| **Age**                     |                     |                       |
| ≤66 years                   | 0.091               | 0.003                 |
| >66 years                   | 1.302               | 1.920                 |
| **Gender**                  |                     |                       |
| Female                      | 0.353               | 0.353                 |
| Male                        | 1.156               | 1.246                 |
| **Smoking**                 |                     |                       |
| Never                       | 0.985               | 1.246                 |
| Ever                        | 0.996               | 1.246                 |
| **T stage**                 |                     |                       |
| I-II                        | <0.001              | 2.313                 |
| III-IV                      | 1.557               | 1.246                 |
| **Lymph node metastasis**   |                     |                       |
| Negative                    | <0.001              | 2.507                 |
| Positive                    | 1.843               | 1.429                 |
| **Distant metastasis**      |                     |                       |
| No                          | 0.018               | 1.188                 |
| Yes                         | 1.030               | 0.931                 |
| **TNM stage**               |                     |                       |
| I-II                        | <0.001              | 2.343                 |
| III-IV                      | 1.687               | 0.660                 |
| **IPSLUAD**                 |                     |                       |
| Low-risk                    | <0.001              | 2.178                 |
| High-risk                   | 1.582               | 1.351                 |

Significant values of $P < 0.05$ is indicated in bold.

### TABLE 3  Characteristics of GEO data sets used in this study

| Author          | GEO Accession | Year of publication | Platform                  | Number of patients | Events |
|-----------------|---------------|---------------------|---------------------------|--------------------|--------|
| Nevins et al    | GSE3141       | 2006                | GPL570 [HG-U133_Plus_2]   | 58                 | 32     |
| Tomida et al    | GSE13213      | 2009                | GPL6480                   | 117                | 49     |
| Tsao et al      | GSE14814      | 2010                | GPL96 [HG-U133A]          | 71                 | 35     |
| Staaf et al     | GSE29016      | 2012                | GPL6947                   | 38                 | 28     |
| Rousseaux et al | GSE30219      | 2013                | GPL570 [HG-U133_Plus_2]   | 85                 | 45     |
| Okayama et al   | GSE31210      | 2011                | GPL570 [HG-U133_Plus_2]   | 226                | 35     |
| Botling et al   | GSE37745      | 2012                | GPL570 [HG-U133_Plus_2]   | 106                | 77     |
| Pintilie et al  | GSE50081      | 2013                | GPL570 [HG-U133_Plus_2]   | 127                | 51     |
| Heiskanen et al | GSE68465      | 2015                | GPL96 [HG-U133A]          | 442                | 236    |

### 3.8  Pathway enrichment analysis of IPSLUAD

To further investigate molecular functions of IPSLUAD in immune systems, a GSEA was performed based on GO Biological Process Ontology and KEGG gene sets. Two significant immune-related pathways were identified, namely innate immune response activating cell surface receptor signaling and interleukin 1 mediated signaling pathway (Figure 8A-D). Again, close associations between genes of IPSLUAD and innate immunities were validated through this result.
FIGURE 5 Prediction performances of IPSLUAD in validating data sets. Kaplan-Meier survival curves of overall survivals in (A) GSE3141, (B) GSE13213, (C) GSE14814, (D) GSE29016, (I) GSE30219, (J) GSE31210, (K) GSE37745, (L) GSE50081, (Q) GSE68465. Receiver operating curve (ROC) analysis of IPSLUAD in (E) GSE3141, (F) GSE13213, (G) GSE14814, (H) GSE29016, (M) GSE30219, (N) GSE31210, (O) GSE37745, (P) GSE50081, (R) GSE68465.
DISCUSSION

With rapid developments of molecular biology and high-throughput sequencing, contributions of tumor microenvironment to cancer developments, progressions, and metastases have been increasingly acknowledged in recent years.\textsuperscript{32,33} There is a complex dynamic crosstalk between tumor and non-cancer cells including infiltrated immune cells and adjacent stroma cells.\textsuperscript{32} However, tumors are considered as autonomous subjects by TNM staging system, which ignores significant effects of TIME. In the present study, a novel 4-gene immune-related prognostic signature was developed to assist TNM staging for more accurate predictions.

Several immune-related signatures for LUAD have been used to divide patients into different prognostic subgroups in previous researches.\textsuperscript{14-16} A list of genes for model constructions was extracted from public immune databases or through differential analyses. In contrast, we applied a different selection method based on co-expression networks, which might

| Study        | Number of genes | Gene list                                                                 |
|--------------|-----------------|---------------------------------------------------------------------------|
| Li et al     | 5               | SLCO4C1, ELAC1, HLF, ZNF204P, ST3GAL5                                      |
| Yue et al    | 3               | ADAM12, BTK, ERG                                                          |
| Song et al   | 30              | PSMC6, LIFR, PIK3CG, CTF1, RELA, MAP3K8, HLA-DOB, LGR4, RXRB, CD79A, ADIPOR2, CCL20, PTPN6, HSPA4, GPI, ADM, IL22RA1, ANGPTL4, XCR1, AP3B1, RFXAP, HSPA2, IL23R, PDGFB, DKK1, PAK4, PSMD2, VEGFC, SHC1, HGF |

![Comparison of different immune signatures](image)

**FIGURE 6** Comparisons of IPSLUAD with other published immune-related models in GSE31210 and GSE68465 data sets. A, Two-year ROC in GSE31210. B, Five-year ROC in GSE31210. C, Two-year ROC in GSE68465. D, Five-year ROC in GSE68465.
identify immune-related genes that had not been reported. In addition, by means of deliberately adding noises during model constructions, IPSLUAD was found to be robust with respect to OS predictions in various independent data sets. Both multivariate and subgroup analyses stratified through TNM staging suggested that IPSLUAD be used as an independent prognostic factor. Furthermore, IPSLUAD outperformed other immune-related signatures in both early-stage LUAD and multicenter cohorts. Therefore, IPSLUAD could not only significantly supplement traditional staging systems, but also be used as an accurate OS predictor for patients with LUAD.

Among the four genes in IPSLUAD, ECT2, and PPIA were widely studied in previous researches. ECT2 was recognized as an oncogenic gene necessary for Kras-Trp53 lung tumorigenesis in vivo. Liu et al also reported on collaborations of ECT2 with growths of lung squamous cell carcinomas promoted by PRKCI. It was suggested by Meta-Analysis that ECT2 was a promising prognostic factor in cancers. PPIA is a housekeeping gene involved in several cancers including NSCLC, pancreatic adenocarcinomas as well as head, and neck squamous cell carcinomas. PPIA was also reported to participate in tumor proliferations and invasions. However, relationships between immune cells and these genes have not been illustrated. Although little is known about roles of ARNTL2 and TUBA4A in LUAD, ARNTL2 was reported to be associated with tumor progressions and metastases in colorectal and breast cancers. TUBA4A was found highly expressed in exosomes secreted by NSCLC cell lines in vitro. Underlying mechanisms of these two genes in LUAD still need further cellular-level explorations.

Infiltrated immune cells constitute important parts of tumors and have been widely studied in recent years. Certain immune cell types were found to be indicative of responses to immunotherapies and OSs. Based on quantifications and locations of demonstrated T cells, the immunoscore developed by Galon et al showed superior predictive accuracies in prognoses compared to that of traditional TNM staging in colorectal carcinomas. High-level expressions of PD1 or PD1 and CTLA4 on infiltrated CD8+ T cells were reported to be predictive of responses to ICIs in NSCLC. In addition, dysfunctional
T cells were also considered as predictive markers of immunotherapeutic responses in melanomas. Since T cells were at the central position of antitumor immunity, a novel algorithm named ImmuCellAI was implemented to evaluate the abundance of infiltrated immune cells in TCGA cohort. Compositions of 18 T cell subsets can be calculated by ImmuCellAI, which is of superior accuracies than other frequently-used methods including Cibersort and Timer. In addition to differences in multiple T cell subsets among IPSLUAD subgroups, one more intriguing finding was the significantly different pattern of innate immune systems.

In respect of innate immunity, some types of cells including DCs and macrophages are context-specific that may exert either protumorigenic or antitumorigenic functions. The most popular “don’t eat me” signals including CD47 and CD24 have been extensively studied, and drugs targeted at these molecules are currently under prudent trials. High expressions of CD47 were also found to be associated with worse prognoses in various types of tumors. Through previous researches, innate immunity might play a more important role in the field of antitumor therapies. However, clinical significances of different innate immune statuses observed among IPSLUAD subgroups need further systematic explorations.

There were several limitations that should be stated in the present study. First, missing data and selection biases were inevitable as this was a retrospective study. Second, values of gene expressions extracted from RNA-seqs or microarrays were all relative. Thus, absolute thresholds for stratifications among different cohorts could not be calculated. Since median cutoff values were used in each data set, accurate external validations would be needed in the future. Third, due to lack of data about immunotherapies, we were unable to investigate relationships between IPSLUADs and responses of ICIs.

### Table 5

| Marker          | IPSLUAD | Low, median (IQR) | High, median (IQR) | P value |
|-----------------|---------|-------------------|--------------------|---------|
| **CD8^+ T cell** |         |                   |                    |         |
| CD8A            | 2.39 (1.87, 2.95) | 2.55 (1.82, 3.18) | 0.148              |
| CD8B            | 1.56 (1.08, 2.17) | 1.68 (1.13, 2.35) | 0.136              |
| **CD4^+ T cell** |         |                   |                    |         |
| CD4             | 4.36 (3.80, 4.71) | 4.19 (3.70, 4.60) | **0.035**          |
| Neutrophil      |         |                   |                    |         |
| CD66b           | 0.12 (0.04, 0.44) | 0.06 (0.02, 0.15) | **<0.001**         |
| CD11b           | 2.79 (2.26, 3.27) | 2.72 (2.06, 3.22) | **0.315**          |
| **Natural killer cell** |         |                   |                    |         |
| CD56            | 0.42 (0.23, 0.71) | 0.30 (0.16, 0.61) | **0.001**          |
| CD16            | 4.36 (3.78, 4.94) | 4.61 (4.03, 5.16) | **<0.001**         |
| CD94            | 0.41 (0.26, 0.68) | 0.50 (0.30, 0.79) | **0.014**          |
| **M1 Macrophage** |         |                   |                    |         |
| CD86            | 2.81 (2.27, 3.18) | 2.87 (2.41, 3.31) | 0.139              |
| CD80            | 1.04 (0.67, 1.35) | 1.04 (0.72, 1.40) | 0.533              |
| iNOS            | 0.57 (0.34, 0.90) | 0.65 (0.37, 0.97) | 0.120              |
| **M2 Macrophage** |         |                   |                    |         |
| CD163           | 3.65 (3.07, 4.15) | 3.75 (3.03, 4.39) | 0.178              |
| CD206           | 3.79 (2.92, 4.32) | 3.49 (2.64, 4.17) | **0.033**          |
| **Monocyte**    |         |                   |                    |         |
| CD14            | 4.86 (4.40, 5.26) | 5.00 (4.46, 5.48) | **0.043**          |
| CD33            | 1.31 (0.92, 1.72) | 1.24 (0.83, 1.62) | 0.156              |
| CD172a          | 3.49 (3.06, 3.84) | 3.56 (3.08, 3.94) | 0.107              |
| **B cell**      |         |                   |                    |         |
| CD19            | 1.65 (0.94, 2.40) | 1.25 (0.78, 1.76) | **<0.001**         |
| CD79A           | 4.03 (3.02, 4.78) | 3.40 (2.76, 4.18) | **<0.001**         |
| **Dendritic cell** |         |                   |                    |         |
| CD11c           | 2.90 (2.50, 3.38) | 2.77 (2.39, 3.28) | **0.035**          |
| CD205           | 1.77 (1.39, 2.13) | 1.82 (1.38, 2.27) | 0.160              |
| HLA-DRA         | 8.17 (7.62, 8.68) | 8.00 (7.32, 8.46) | **0.002**          |
| **Th**          |         |                   |                    |         |
| BCL6            | 3.71 (3.46, 4.00) | 3.58 (3.34, 3.90) | **0.001**          |
| CD185           | 0.16 (0.06, 0.35) | 0.10 (0.04, 0.20) | **<0.001**         |
| CD278           | 1.27 (0.85, 1.69) | 1.31 (0.90, 1.82) | 0.417              |
| **Th17**        |         |                   |                    |         |
| CD196           | 0.23 (0.10, 0.41) | 0.13 (0.05, 0.28) | **<0.001**         |
| RORC            | 3.39 (2.85, 3.86) | 3.20 (2.52, 3.59) | **<0.001**         |
| STAT3           | 4.82 (4.57, 5.03) | 4.76 (4.46, 4.98) | **0.033**          |
| **Th1**         |         |                   |                    |         |
| CD183           | 2.26 (1.70, 2.79) | 2.15 (1.60, 2.73) | 0.472              |

(Continues)
FIGURE 8  Different immune statuses between low-risk and high-risk groups in TCGA-LUAD cohort. A and B, Significant enrichments of immune-related pathways among high-risk patients were indicated through gene set enrichment analysis (GSEA). C and D, Gene sets between low-risk and high-risk groups were analyzed through expression profiles of the two enrichments.
5  |  CONCLUSIONS

In conclusion, a robust immune-related prognostic signature was developed and validated in nine independent data sets. Different innate immune statuses were observed between low-risk and high-risk groups. This signature may serve as a promising prognostic biomarker for LUADs in the future.

ACKNOWLEDGEMENTS

This study was supported by the National Key R&D Program of China (2017YFC1311000, 2018YFC1312100), CAMS Initiative for Innovative Medicine (2017-2IM-1-005, 2017-2IM-2-003, 2019-2IM-2-002), Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences (2018PT32033, 2017PT32017), Innovation team development project of Ministry of Education (IRT_17R10), and Peking Union Medical College Youth Fund (3332018144). We thank all the staff in the Department of Thoracic Surgery for their support during the study.

CONFLICT OF INTEREST

The authors declare that they have no competing interest.

AUTHORS’ CONTRIBUTIONS

YG, SG, and JH conceived and designed the study. ZW, XW, GZ, HZ, and RL collected the data. SS performed data analysis. SS and WG wrote the paper. BQ, FT, YG, and QX reviewed and edited the manuscript. All authors read and approved the manuscript.

DATA AVAILABILITY STATEMENT

The data sets analysed during the current study are available in the TCGA (https://portal.gdc.cancer.gov/) and GEO repository (https://www.ncbi.nlm.nih.gov/geo/).

ORCID

Wei Guo https://orcid.org/0000-0001-8302-8292
Yibo Gao https://orcid.org/0000-0002-0501-9814
Jie He https://orcid.org/0000-0002-0285-5403

REFERENCES

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424.
2. Lubin JH, Blot WJ. Assessment of lung cancer risk factors by histologic category. J Natl Cancer Inst. 1984;73(2):383-389.
3. Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008;83(5):584-594.
4. Charloux A, Quoix E, Wolkove N, Small D, Pauli G, Kreisman H. The increasing incidence of lung adenocarcinoma: reality or artefact? A review of the epidemiology of lung adenocarcinoma. Int J Epidemiol. 1997;26(1):14-23.
5. Bronte G, Rizzo S, La Paglia L, et al. Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma. Cancer Treat Rev. 2010;36:S21-S29.
6. Saito M, Suzuki H, Kono K, Takenoshita S, Kohno T. Treatment of lung adenocarcinoma by molecular-targeted therapy and immunotherapy. Surg Today. 2018;48(1):1-8.
7. Page DB, Postow MA, Callahan MK, Allison JP, Wolchok JD. Immune modulation in cancer with antibodies. Annu Rev Med. 2014;65:185-202.
8. Ribas A. Releasing the brakes on cancer immunotherapy. N Engl J Med. 2015;373(16):1490-1492.
9. Taube JM, Galon J, Sholl LM, et al. Implications of the tumor immune microenvironment for staging and therapeutics. Mod Pathol. 2018;31(2):214-234.
10. Schaer DA, Beckmann RP, Dempsey JA, et al. The CDK4/6 inhibitor abemaciclib induces a T cell inflamed tumor microenvironment and enhances the efficacy of PD-L1 checkpoint blockade. Cell Rep. 2018;22(11):2978-2994.
11. Newman AM, Liu CL, Green MR, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12(5):453-457.
12. Li T, Fan J, Wang B, et al. TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells. Can Res. 2017;77(21):e108-e110.
13. Miao Y-R, Zhang Q, Lei Q, et al. ImmuCellAI: a unique method for comprehensive T-cell subsets abundance prediction and its application in cancer immunotherapy. bioRxiv. 2019;872184.
14. Li J, Wang H, Li Z, et al. A 5-gene signature is closely related to tumor immune microenvironment and predicts the prognosis of patients with non-small cell lung cancer. Biomed Res Int. 2020;2020:1-9.
15. Song Q, Shang J, Yang Z, et al. Identification of an immune signature predicting prognosis risk of patients in lung adenocarcinoma. J Transl Med. 2019;17(1):70.
16. Yue C, Ma H, Zhou Y. Identification of prognostic gene signature associated with microenvironment of lung adenocarcinoma. PeerJ. 2019;7:e8128.
17. Davis S, Meltzer PS. GEOquery: a bridge between the Gene Expression Omnibus (GEO) and BioConductor. Bioinformatics. 2007;23(14):1846-1847.
18. Yoshihara K, Shahmoradgoli M, Martinez E, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4(1):1-11.
19. Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics. 2008;9(1):559.
20. Sill M, Hielscher T, Becker N, Zucknick M. c060: extended inference with lasso and elastic-net regularized Cox and generalized linear models. J Stat Softw. 2014;62(5):1-22.
21. Bild AH, Yao G, Chang JT, et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature. 2006;439(7074):353-357.
22. Botling J, Edlund K, Lohr M, et al. Biomarker discovery in non-small cell lung cancer: integrating gene expression profiling, meta-analysis, and tissue microarray validation. Clin Cancer Res. 2013;19(1):194-204.
23. Der SD, Sykes J, Pintilie M, et al. Validation of a histology-independent prognostic gene signature for early-stage, non–small-cell lung cancer including stage IA patients. J Thorac Oncol. 2014;9(1):59-64.
24. Okayama H, Kohno T, Ishii Y, et al. Identification of genes up-regulated in ALK-positive and EGFR/KRAS/ALK-negative lung adenocarcinomas. *Can Res*. 2012;72(1):100-111.

25. Rousseaux S, Debernardi A, Jacquiau B, et al. Ectopic activation of germline and placental genes identifies aggressive metastasis-prone lung cancers. *Sci Transl Med*. 2013;5(186):186ra66.

26. Staaf J, Jönsson G, Jönsson M, et al. Relation between smoking history and gene expression profiles in lung adenocarcinomas. *BMC Med Genom*. 2012;5(1):22.

27. Tomida S, Takeuchi T, Shimada Y, et al. Relapse-related molecular signature in lung adenocarcinomas identifies patients with dismal prognosis. *J Clin Oncol*. 2010;28(29):4417–4424.

28. Zhu C-Q, Ding K, Strumpf D, et al. Prognostic and predictive gene signature for adjuvant chemotherapy in resected non–small-cell lung cancer. *J Clin Oncol*. 2010;28(29):4417–4424.

29. Shedden K, Taylor JM, Einkemann SA, et al. Gene expression–based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. *Nat Med*. 2008;14(8):822.

30. Zhang X, Lan Y, Xu J, et al. CellMarker: a manually curated source of cell markers in human and mouse. *Nucleic Acids Res*. 2019;47(D1):D721-D728.

31. Subramanian A, Kuehn H, Gould J, Tamayo P, Mesirov JP. GSEA-P: a desktop application for Gene Set Enrichment Analysis. *Bioinformatics*. 2007;23(23):3251–3253.

32. GarnerHannah, de Visser Karin E.. Immune crosstalk in cancer progression and metastatic spread: a complex conversation. *Nature Reviews Immunology*. 2020. http://dx.doi.org/10.1038/s41577-019-0271-z

33. Joyce JA, Fearon DT. T cell exclusion, immune privilege, and the tumor microenvironment. *Science*. 2015;348(6230):74-80.

34. Justilien V, Ali SA, Jamieson L, et al. Ect2-dependent rRNA synthesis is required for KRAS-TRP53-driven lung adenocarcinoma. *Cancer Cell*. 2017;31(2):256-269.

35. Liu Y, Yin N, Wang X, et al. Chromosome 3q26 gain is an early event driving coordinated overexpression of the PRKCI, SOX2, and ECT2 oncogenes in lung squamous cell carcinoma. *Cell Rep*. 2020;30(3):771–782.e6.

36. Li B, Lin J-P, Li Z, Yin C, Yang J-B, Meng Y-Q. Clinicopathological and prognostic significance of epithelial cell transforming sequence 2 expression in cancers: a systematic review and meta-analysis. *Artif Cells Nanomed Biotechnol*. 2019;47(1):4139-4148.

37. Campa MJ, Wang MZ, Howard B, Fitzgerald MC, Patz EF. Protein expression profiling identifies macrophage migration inhibitory factor and cyclophilin a as a potential molecular targets in non-small cell lung cancer. *Can Res*. 2003;63(7):1652-1656.

38. Takahashi M, Suzuki S, Ishikawa K. Cyclophilin A-EMMPRIN interaction induces invasion of head and neck squamous cell carcinoma. *Oncol Rep*. 2012;27(1):198-203.

39. Li M, Wang H, Li F, Fisher WE, Chen C, Yao Q. Effect of cyclophilin A on gene expression in human pancreatic cancer cells. *Am J Surg*. 2005;190(5):739-745.

40. Li Z, Zhao X, Bai S, et al. Proteomics identification of cyclophilin a as a potential prognostic factor and therapeutic target in endometrial carcinoma. *Mol Cell Proteomics*. 2008;7(10):1810-1823.

41. Mazzoccoli G, Piazzina V, Panza A, et al. ARNTL2 and SERPINE1: potential biomarkers for tumor aggressiveness in colorectal cancer. *J Cancer Res Clin Oncol*. 2012;138(3):501-511.

42. Ha NH, Long J, Cai Q, Shu XO, Hunter KW. The circadian rhythm gene Arntl2 is a metastasis susceptibility gene for estrogen receptor-negative breast cancer. *PLoS Genet*. 2016;12(9):e1006267.

43. Pan D, Chen J, Feng C, et al. Preferential localization of MUC1 glycoprotein in exosomes secreted by non-small cell lung carcinoma cells. *Int J Mol Sci*. 2019;20(2):323.

44. Galon J, Mlecnik B, Bindea G, et al. Towards the introduction of the *Immunoscore* in the classification of malignant tumours. *J Pathol*. 2014;232(2):199-209.

45. Quck L, David MD, Kennedy A, et al. Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib. *Nat Med*. 2018;24(8):1167-1177.

46. Daud AI, Loo K, Pauli ML, et al. Tumor immune profiling predicts response to anti–PD-1 therapy in human melanoma. *J Clin Investig*. 2016;126(9):3447-3452.

47. Gajewski TF, Schreiber H, Fu Y-X. Innate and adaptive immune cells in the tumor microenvironment. *Nat Immunol* 2013;14(10):1014–1022.

48. Barkal AA, Brewer RE, Markovic M, et al. CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy. *Nature*. 2019;572(7769):392-396.

49. Willingham SB, Volkmer J-P, Gentles AJ, et al. The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. *Proc Natl Acad Sci USA*. 2012;109(17):6662-6667.

50. Russ A, Hua AB, Montfort WR, et al. Blocking “don’t eat me” signal of CD47-SIRPα in hematological malignancies, an in-depth review. *Blood Rev*. 2018;32(6):480-489.

**SUPPORTING INFORMATION**

Additional supporting information may be found online in the Supporting Information section.

---

**How to cite this article:** Sun S, Guo W, Wang Z, et al. Development and validation of an immune-related prognostic signature in lung adenocarcinoma. *Cancer Med*. 2020;9:5960–5975. [https://doi.org/10.1002/cam4.3240](https://doi.org/10.1002/cam4.3240)